The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Open accessAbstract
When spores of the anaerobic bacterium Clostridium novyi-NT are systemically injected into animals, they germinate exclusively within the hypoxic regions of cancers. The germinated bacteria destroy adjacent tumor cells but spare a rim of well oxygenated tumor cells that subsequently expand. Surprisingly, we found that ≈30% of mice treated with such spores were cured of their cancers despite the viable tumor rim initially remaining after spore germination. The mechanism underlying this effect was shown to be immune-mediated, because cured animals rejected a subsequent challenge of the same tumor. Similar effects were observed in rabbits with intrahepatic tumors. It was particularly notable that the induced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate large established tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
Kay, A. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440106 · Cited by 1,368
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
Self-citationHuman Toll-Like Receptors Mediate Cellular Activation by Mycobacterium tuberculosis
Means, T. K., Wang, S., Lien, E., Yoshimura, A., Golenbock, D. T., & Fenton, M. J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.3920 · Cited by 804
Combination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563
Self-citationLow, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., et al. (1999) · Nature Biotechnology · doi:10.1038/5205 · Cited by 476
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Eriksson, U., Ricci, R., Hunziker, L., Kurrer, M. O., Oudit, G. Y., Watts, T. H., Sonderegger, I., Bachmaier, K., Kopf, M., & Penninger, J. M. (2003) · Nature Medicine · doi:10.1038/nm960 · Cited by 405
Tumor‐specific shared antigenic peptides recognized by human T cells
Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J., Van den Eynde, B. J., Brasseur, F., & Boon, T. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18806.x · Cited by 378
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Liu, S.-C., Minton, N., Giaccia, A., & Brown, J. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301659 · Cited by 194
Hernandez‐Ilizaliturri, F. J., Jupudy, V., Ostberg, J. R., Oflazoglu, E., Huberman, A., Repasky, E. A., & Czuczman, M. S. (2003) · PubMed · Cited by 188
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria
Bettegowda, C., Dang, L. H., Abrams, R., Huso, D. L., Dillehay, L., Cheong, I., Agrawal, N., Borzillary, S., McCaffery, J. M., Watson, E. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036598100 · Cited by 172
Self-citationShedding Light on Immunotherapy for Cancer
Rosenberg, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmcibr045001 · Cited by 150
Mouse B7-H3 induces antitumor immunity
Sun, X., Vale, M., Leung, E. Y., Kanwar, J. R., Gupta, R., & Krissansen, G. W. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302070 · Cited by 137
Can engineered bacteria help control cancer?
Jain, R. K., & Forbes, N. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261606598 · Cited by 104
Targeting Vascular and Avascular Compartments of Tumors withC. novyi-NTand Anti-microtubule Agents
Dang, L. H., Bettegowda, C., Agrawal, N., Cheong, I., Huso, D. L., Frost, P., Loganzo, F., Greenberger, L. M., Barkóczy, J., Pettit, G. R., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.704 · Cited by 97
Self-citationThe liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium
Heppner, F. L., & M�se, J. R. (1978) · Acta Neurochirurgica · doi:10.1007/bf01406639 · Cited by 90
McGUIGAN, C. C., Penrice, G., Gruer, L. D., Ahmed, S. F., GOLDBERG, D., Black, M., Salmon, J. E., & HOOD, J. (2002) · Journal of Medical Microbiology · doi:10.1099/0022-1317-51-11-971 · Cited by 90
Matsumura, H., Takeuchi, A., & Kano, Y. (1997) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.61.1211 · Cited by 82
Dai, J., Liu, B., Caudill, M. M., Zheng, H., Qiao, Y., Podack, E. R., & Li, Z. (2003) · PubMed · Cited by 82
Tumor-Specific Gene Delivery Using Genetically Engineered Bacteria
Theys, J., Barbé, S., Landuyt, W., Nuyts, S., Mellaert, L. V., Wouters, B. G., Anné, J., & Lambin, P. (2003) · Current Gene Therapy · doi:10.2174/1566523034578357 · Cited by 54
Cancer Vaccines: An Old Idea Comes of Age
Emens, L. A., & Jaffee, E. M. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.217 · Cited by 39
A New Twist on Autologous Cancer Vaccines
Emens, L. A. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.2.283 · Cited by 35
Weiss, J. M., Shivakumar, R., Feller, S., Li, L., Hanson, A., Fogler, W. E., Fratantoni, J. C., & Liu, L. N. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700686 · Cited by 22
Finn, S. P., Leen, E., English, L., & O’Briain, D. S. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-1465-afiaoo · Cited by 22
Tumor immunology—towards a paradigm of reciprocal research
Drake, C. G., & Pardoll, D. M. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0403 · Cited by 18
Self-citation
Cited by
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Self-citationBacteria-cancer interactions: bacteria-based cancer therapy
Duong, M. T.-Q., Qin, Y., You, S.-H., & Min, J.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0297-0 · Cited by 519
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400
“novyi-NT has been shown to induce a potent antitumor immune response (20), we sought to determine whether canine soft tumor sarcomas were genetically similar to those of humans and, as such, would be a suitable comparative model.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., Abusedera, M., Wahl, R. L., Kinzler, K. W., Zhou, S., Huso, D. L., & Vogelstein, B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-10-07
- Volume
- 101
- Issue
- 42
- Pages
- 15172-15177
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2014073110
- Cited by
- 304
- References
- 29
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.